NCT00604331

Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Herzzentrum Goettingen · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Pyruvate is an intermediate of energy metabolism and was shown to possess pronounced positive inotropic effects in vitro and in vivo without altering myocardial oxygen consumption. Moreover, it was shown that the effects of beta-adrenergic stimulation were potentiated. Thus, it might be possible to save catecholamines in patients with severe heart failure or cardiogenic shock. This study was designed to test the hemodynamic effects of pyruvate administered into a coronary artery in addition to intra-aortic balloon pump counterpulsation in patients with severe heart failure or in patients with acute myocardial infarction and cardiogenic shock after having performed percutaneous coronary intervention. A pronounced improvement in hemodynamics is expected to occur.

Conditions

• Shock, Cardiogenic
• Heart Failure
• Acute Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Pyruvate	sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2008-01-30
• Last updated: 2010-12-09

Locations

1 site across 1 country: Germany